• APX002 (AD002): An investigational oral medication in clinical development for the treatment of obstructive sleep apnea (OSA).
• APX001: An earlier-stage investigational oral drug candidate also being developed for the treatment of obstructive sleep apnea (OSA).

Apnimed (APMD) is a clinical-stage pharmaceutical company focused on the development of novel oral pharmacologic treatments for sleep apnea. As of its current operational stage, the company does not have any commercialized products available for sale to end-users (individuals) or other companies.

Therefore, Apnimed does not currently have major customers that purchase its products or services in the traditional sense.

Kevin R. Lind, Chief Executive Officer

Kevin R. Lind was appointed Chief Executive Officer of Apnimed effective June 2, 2026. Prior to joining Apnimed, he co-founded Longboard Pharmaceuticals, Inc., a private biopharmaceutical company, where he served as President and Chief Executive Officer from February 2020 to December 2024. Longboard Pharmaceuticals was subsequently acquired by H. Lundbeck A/S. Before Longboard, Mr. Lind was the Executive Vice President and Chief Financial Officer of Arena Pharmaceuticals, Inc. from June 2016 to February 2020. He also gained experience in healthcare investing at TPG Special Situations Partners and TPG from 2006 to 2016.

Michael Kelly, Chief Financial Officer

Michael Kelly was appointed Chief Financial Officer of Apnimed on July 1, 2026. He brings over 25 years of healthcare finance leadership experience to the role. Most recently, Mr. Kelly served as Global Co-Head of Healthcare Investment Banking at Cantor Fitzgerald, where he was instrumental in building and leading a global biopharmaceutical franchise and executed more than $30 billion in capital markets and M&A transactions.

Dennis Molnar, President and Chief Operating Officer

Dennis Molnar joined Apnimed in August 2018 as Chief Operating Officer and was promoted to President and Chief Operating Officer in March 2024. Before Apnimed, he served as Chief Executive Officer of Helperby Therapeutics LTD's U.S. operations from 2016 to 2018.

Graham Goodrich, Chief Commercial Officer

Graham Goodrich joined Apnimed as Chief Commercial Officer in January 2024. He possesses an extensive background of more than 25 years in commercial leadership, with a track record of successfully launching and marketing transformative brands, including his previous role as a member of the Commercial leadership team and SVP, Brand Marketing at Biohaven.

Luigi Taranto, Chief Scientific Officer

Luigi Taranto is one of the scientific founders of Apnimed and serves as its Chief Scientific Officer. His foundational research at Brigham and Women's Hospital established the proof of concept for Apnimed's first combination of drugs for obstructive sleep apnea. Before officially joining Apnimed in early 2020, Dr. Taranto led the sleep apnea drug discovery program at Andrew Wellman's laboratory at Harvard.

Key Risks to Apnimed's Business

1. Clinical Development and Regulatory Approval Risk: Apnimed's business heavily relies on the successful clinical development and subsequent regulatory approval of its lead product candidate, AD109, for obstructive sleep apnea (OSA). While AD109 has reported positive topline results from Phase 3 clinical trials (SynAIRgy and LunAIRo) and its New Drug Application (NDA) has been accepted by the U.S. Food and Drug Administration (FDA), there is always inherent uncertainty in the regulatory process, and final approval is not guaranteed. Any delays or failure to obtain regulatory approval would significantly impact the company's prospects.
2. Commercialization and Market Acceptance Risk: Even if AD109 receives regulatory approval, Apnimed faces substantial risks in successfully commercializing and gaining market acceptance for its oral therapy in the competitive OSA treatment landscape. The current standard of care for OSA often involves devices like Continuous Positive Airway Pressure (CPAP) machines, and patients may be resistant to new treatment paradigms. The company must effectively differentiate AD109, secure favorable reimbursement, and achieve broad adoption among patients and healthcare providers against established treatments and potential new entrants.
3. Competition and Intellectual Property Protection: Apnimed operates in a highly competitive pharmaceutical market, with other companies actively developing treatments for sleep-related breathing disorders. Competitors include established players like ResMed, Philips, Inspire Medical Systems, Jazz Pharmaceuticals, Idorsia, Takeda, and Merck. The success of Apnimed depends on its ability to protect its intellectual property related to AD109 and future pipeline candidates. Any challenges to its patents or the development of more effective or convenient alternative treatments by competitors could significantly erode its market share and profitability.

• For the U.S. region, the market includes approximately 80 million adults with OSA.
• Globally, the market includes approximately 1 billion people with OSA.

Here are 3-5 expected drivers of future revenue growth for Apnimed (APMD) over the next 2-3 years:

1. FDA Approval and Commercialization of AD109 (Oximbi) for Obstructive Sleep Apnea (OSA): Apnimed's primary driver of future revenue growth hinges on the anticipated FDA approval and subsequent commercial launch of its lead product candidate, AD109 (also known as Oxnimbi), a novel oral therapy for obstructive sleep apnea. The company submitted a New Drug Application (NDA) for AD109 to the FDA in April 2026, with an expected decision in the first quarter of 2027. Successful approval and market introduction would enable Apnimed to generate significant revenue from sales of this once-daily oral pill.

2. Penetration of the Large and Underserved Obstructive Sleep Apnea (OSA) Market: The market for OSA treatment represents a substantial opportunity, with an estimated 80 million adults in the U.S. and approximately 1 billion people worldwide affected by the condition. A significant portion of these individuals remain undiagnosed, untreated, or inconsistently treated with existing device-based therapies. As a potential first-in-class oral pharmacotherapy addressing the underlying neuromuscular cause of OSA, AD109 is positioned to capture a considerable share of this underserved market by offering a more convenient and potentially more adherent treatment option compared to traditional devices.

3. Expansion into the Primary Care Market for OSA Treatment: Apnimed anticipates that an oral therapy like AD109 could facilitate a shift in the OSA treatment paradigm, potentially expanding beyond sleep specialists to primary care physicians. This broader access and simplified intervention could lead to increased diagnoses and treatment initiation, significantly growing the patient base for AD109 and, consequently, Apnimed's revenue.

4. Future Product Development and Pipeline Expansion for Sleep-Related Breathing Disorders: While AD109 is the immediate focus, Apnimed is also engaged in preclinical-stage programs targeting other sleep-related breathing disorders and associated comorbidities. The company has indicated that proceeds from its IPO may be allocated to further research and development activities, as well as potential in-licensing or acquisitions of complementary businesses or technologies. These initiatives could lead to the development and launch of additional products, diversifying Apnimed's revenue streams in the long term.

5. Royalty Revenue from Strategic Joint Venture Monetization: Apnimed recently strengthened its balance sheet and future revenue prospects by monetizing its 50% ownership in the Shionogi-Apnimed Sleep Science (SASS) joint venture. This transaction provides Apnimed with tiered royalties on future commercial sales of any products arising from SASS intellectual property. These royalty payments will serve as a consistent, non-product-based revenue stream for Apnimed over the next several years.

Share Issuance

• Apnimed has raised substantial capital through private funding rounds, with reported total funding of $249 million over nine rounds.
• In early 2026, the company completed a Series D-1 preferred stock financing, raising $25 million.
• On July 10, 2026, Apnimed filed for an IPO to list its common stock on the Nasdaq Global Market under the ticker symbol APMD, with estimated proceeds of $100 million, though the exact terms (number of shares, price range) were not yet disclosed.

Inbound Investments

• In April 2026, Apnimed secured a senior secured credit facility for up to $150 million with HealthCare Royalty Partners (HCRx), receiving $50 million at closing, with additional tranches contingent on FDA approval and sales milestones.
• The company received a $100 million upfront cash payment in early 2026 from Shionogi & Co. Ltd, as part of an agreement for Shionogi to acquire Apnimed's 50% ownership in their Shionogi-Apnimed Sleep Science (SASS) joint venture.
• Apnimed raised $25 million in Series D-1 preferred stock in early 2026, adding to its previous funding rounds which included investments from Sectoral Asset Management, Morningside Venture Partners, and Alpha Wave Ventures.

Outbound Investments

• Apnimed established a joint venture called Shionogi-Apnimed Sleep Science (SASS) in 2023 with Shionogi & Co. Ltd.
• In April 2025, Apnimed acquired the intellectual property and exclusive global rights to develop and commercialize sulthiame for sleep apnea from Desitin Arzneimittel GmbH.

Capital Expenditures

• While specific capital expenditure figures are not publicly detailed, Apnimed's capital allocation has heavily focused on the research and development (R&D) of its lead oral drug candidate, AD109 (Oximbi), which has completed two Phase 3 clinical trials for obstructive sleep apnea.
• Proceeds from the anticipated IPO, along with existing cash, are earmarked to fund the regulatory approval process and potential commercial launch of Oxnimbi, as well as continued R&D activities and general corporate purposes.